Phase 2 Study of Apixaban Reversal by Ciraparantag as Measured by WBCT

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
This study is a randomized, single-blind, placebo-controlled study to assess the efficacy and safety of ciraparantag administered to healthy volunteers anticoagulated with apixaban measuring clotting times using Whole Blood Clotting Time (WBCT).
Epistemonikos ID: acc75e19d2a29432240dae77fdd5507ec087e8bc
First added on: May 21, 2024